211 related articles for article (PubMed ID: 26052612)
1. Safety profile of a liquid formulation of deferiprone in young children with transfusion-induced iron overload: a 1-year experience.
Chuansumrit A; Songdej D; Sirachainan N; Wongwerawattanakoon P; Kadegasem P; Sasanakul W
Paediatr Int Child Health; 2016 Aug; 36(3):209-13. PubMed ID: 26052612
[TBL] [Abstract][Full Text] [Related]
2. Safety profile of a liquid formulation of deferiprone in young children with transfusion-induced iron overload: a 1-year experience.
Chuansumrit A; Songdej D; Sirachainan N; Wongwerawattanakoon P; Kadegasem P; Sasanakul W
Paediatr Int Child Health; 2016 Jan; ():1-5. PubMed ID: 27077621
[TBL] [Abstract][Full Text] [Related]
3. The safety, tolerability, and efficacy of a liquid formulation of deferiprone in young children with transfusional iron overload.
ElAlfy MS; Sari TT; Lee CL; Tricta F; El-Beshlawy A
J Pediatr Hematol Oncol; 2010 Nov; 32(8):601-5. PubMed ID: 20921906
[TBL] [Abstract][Full Text] [Related]
4. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
Daar S; Pathare AV
Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
[TBL] [Abstract][Full Text] [Related]
5. Deferiprone (GPO-L-ONE(®) ) monotherapy reduces iron overload in transfusion-dependent thalassemias: 1-year results from a multicenter prospective, single arm, open label, dose escalating phase III pediatric study (GPO-L-ONE; A001) from Thailand.
Viprakasit V; Nuchprayoon I; Chuansumrit A; Torcharus K; Pongtanakul B; Laothamatas J; Srichairatanakool S; Pooliam J; Supajitkasem S; Suriyaphol P; Tanphaichitr VS; Tuchinda S
Am J Hematol; 2013 Apr; 88(4):251-60. PubMed ID: 23460233
[TBL] [Abstract][Full Text] [Related]
6. Comparative Efficacy and Safety of Oral Iron Chelators and their Novel Combination in Children with Thalassemia.
Gomber S; Jain P; Sharma S; Narang M
Indian Pediatr; 2016 Mar; 53(3):207-10. PubMed ID: 27029681
[TBL] [Abstract][Full Text] [Related]
7. The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study.
Totadri S; Bansal D; Bhatia P; Attri SV; Trehan A; Marwaha RK
Pediatr Blood Cancer; 2015 Sep; 62(9):1592-6. PubMed ID: 25820920
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of deferiprone in patients with β-thalassaemia: impact of splenectomy and iron status.
Limenta LM; Jirasomprasert T; Jittangprasert P; Wilairat P; Yamanont P; Chantharaksri U; Fucharoen S; Morales NP
Clin Pharmacokinet; 2011 Jan; 50(1):41-50. PubMed ID: 21028920
[TBL] [Abstract][Full Text] [Related]
9. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
Nolte F; Höchsmann B; Giagounidis A; Lübbert M; Platzbecker U; Haase D; Lück A; Gattermann N; Taupitz M; Baier M; Leismann O; Junkes A; Schumann C; Hofmann WK; Schrezenmeier H
Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603
[TBL] [Abstract][Full Text] [Related]
10. Reduction of body iron stores to normal range levels in thalassaemia by using a deferiprone/deferoxamine combination and their maintenance thereafter by deferiprone monotherapy.
Kolnagou A; Kleanthous M; Kontoghiorghes GJ
Eur J Haematol; 2010 Nov; 85(5):430-8. PubMed ID: 20662901
[TBL] [Abstract][Full Text] [Related]
11. Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience.
El-Beshlawy A; Manz C; Naja M; Eltagui M; Tarabishi C; Youssry I; Sobh H; Hamdy M; Sharaf I; Mostafa A; Shaker O; Hoffbrand AV; Taher A
Ann Hematol; 2008 Jul; 87(7):545-50. PubMed ID: 18351337
[TBL] [Abstract][Full Text] [Related]
12. A trial of deferiprone in transfusion-dependent iron overloaded children.
Lucas GN; Perera BJ; Fonseka EA; De Silva DD; Fernandopulle M
Ceylon Med J; 2000 Jun; 45(2):71-4. PubMed ID: 11051705
[TBL] [Abstract][Full Text] [Related]
13. Comparison of deferiprone and deferrioxamine for the treatment of transfusional iron overload in children with beta thalassemia major.
Waheed N; Ali S; Butt MA
J Ayub Med Coll Abbottabad; 2014; 26(3):297-300. PubMed ID: 25671931
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of early-start deferiprone in infants and young children with transfusion-dependent beta thalassemia: Evidence for iron shuttling to transferrin in a randomized, double-blind, placebo-controlled, clinical trial (START).
Elalfy MS; Hamdy M; Adly A; Ebeid FSE; Temin NT; Rozova A; Lee D; Fradette C; Tricta F
Am J Hematol; 2023 Sep; 98(9):1415-1424. PubMed ID: 37401738
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of deferasirox in multitransfused Indian children with β-thalassaemia major.
Chandra J; Chaudhary H; Pemde H; Singh V; Dutta AK
Ann Trop Paediatr; 2011; 31(1):47-51. PubMed ID: 21262109
[TBL] [Abstract][Full Text] [Related]
16. Experience with the oral iron chelator deferiprone in transfusion-dependent children.
Lucas GN; Perera BJ; Fonseka EA; De Silva DD; Fernandopulle M; Karunatilaka DH; Weerasinghe I
Ceylon Med J; 2002 Dec; 47(4):119-21. PubMed ID: 12661341
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of early start of iron chelation therapy with deferiprone in young children newly diagnosed with transfusion-dependent thalassemia: A randomized controlled trial.
Elalfy MS; Adly A; Awad H; Tarif Salam M; Berdoukas V; Tricta F
Am J Hematol; 2018 Feb; 93(2):262-268. PubMed ID: 29119631
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Combined Oral Chelation with Deferiprone and Deferasirox on Iron Overload in Transfusion Dependent Children with Thalassemia - A Prospective Observational Study.
DivakarJose RR; Delhikumar CG; Ram Kumar G
Indian J Pediatr; 2021 Apr; 88(4):330-335. PubMed ID: 32661609
[TBL] [Abstract][Full Text] [Related]
19. Use of deferiprone for iron chelation in patients with transfusion-dependent thalassaemia.
Jamuar SS; Lai AH; Tan AM; Chan MY; Tan ES; Ng IS
J Paediatr Child Health; 2011 Nov; 47(11):812-7. PubMed ID: 21902752
[TBL] [Abstract][Full Text] [Related]
20. Deferiprone as an oral iron chelator in sickle cell disease.
Voskaridou E; Douskou M; Terpos E; Stamoulakatou A; Meletis J; Ourailidis A; Papassotiriou I; Loukopoulos D
Ann Hematol; 2005 Jul; 84(7):434-40. PubMed ID: 15809885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
